転移性尿路上皮がんの世界市場レポート 2025年

転移性尿路上皮がん市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR19.9％で29億4,000万米ドルに成長します。予測期間の成長は、患者擁護の高まり、がん治療を支援する政府プログラム、バイオ医薬品産業の成長、化学療法の適用拡大、急速な都市化とライフスタイルの変化に起因しています。この期間に予想される主な動向には、免疫療法の進歩、人工知能の統合、製薬企業とバイオテクノロジー企業の提携、遠隔医療の進歩、次世代医薬品の開発などがあります。

膀胱がんの罹患率の増加が転移性尿路上皮がん市場の成長を牽引すると予想されます。膀胱がんは、膀胱組織に悪性細胞が形成される疾患で、一般的には膀胱を覆う尿路上皮細胞から始まる。膀胱がん患者の増加は、喫煙、化学物質への暴露、慢性的な膀胱の炎症、検出方法の改善などの要因に起因しています。転移性尿路上皮がんは膀胱がんの進行性かつ侵攻性の病期を表しているため、早期発見、より良い治療法、研究の増加の必要性を強調し、最終的には膀胱がんの管理における革新を促進し、患者の転帰を改善します。例えば、Cancer Research UKの2023年2月の報告書によると、英国における新規膀胱がん症例数は、2023年から2025年にかけての年間約9,800例から、2038年から2040年には年間約10,700例に増加すると予測されています。このような膀胱がんの有病率の増加が、転移性尿路上皮がん市場の拡大を牽引しています。

また、新たな治療法に対する規制当局の承認も市場の成長に寄与しています。転移性尿路上皮がん領域の主要企業は、薬事承認を取得し、市場範囲を拡大し、局所進行または転移性尿路上皮がん（la/mUC）の成人患者の治療における地位を強化しています。薬事承認とは、医薬品や治療法が一般に販売されることを政府機関が正式に許可することです。例えば、2023年4月、米国の製薬会社Merck &Co.Inc.は、KEYTRUDA（ペムブロリズマブ）について、局所進行性または転移性の尿路上皮がん患者のファーストライン治療薬としてFDAの承認を取得しました。KEYTRUDA（ペムブロリズマブ）とenfortumab vedotinの併用療法は、局所進行性または転移性の尿路上皮がん患者に対する抗体薬物複合体との併用療法として米国で初めて承認された抗PD-1療法であり、今回の承認は尿路上皮がん治療における重要な一歩となります。この併用療法は、従来のプラチナ製剤ベースの化学療法と比較して、全生存期間（OS）および無増悪生存期間（PFS）において統計学的に有意な改善を示し、治療選択肢が限られている患者に新たな選択肢を提供しました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界転移性尿路上皮がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の転移性尿路上皮がん市場：成長率分析
• 世界の転移性尿路上皮がん市場の実績：規模と成長, 2019-2024
• 世界の転移性尿路上皮がん市場の予測：規模と成長, 2024-2029, 2034F
• 世界転移性尿路上皮がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の転移性尿路上皮がん市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 標的療法
• 免疫療法
• 放射線治療
• 膀胱内療法
• 世界の転移性尿路上皮がん市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 尿検査
• 膀胱鏡検査
• 静脈性腎盂造影（IVP）
• 生検
• 世界の転移性尿路上皮がん市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 腫瘍学クリニック
• 調査機関
• その他のエンドユーザー
• 世界の転移性尿路上皮がん市場化学療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プラチナ製剤化学療法
• ゲムシタビンベースの化学療法
• その他の化学療法レジメン
• 世界の転移性尿路上皮がん市場標的療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• FGFR阻害剤
• 免疫チェックポイント阻害剤
• その他の標的エージェント
• 世界の転移性尿路上皮がん市場免疫療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• PD-1またはPD-L1阻害剤
• CTLA-4阻害剤
• 複合免疫療法
• 世界の転移性尿路上皮がん市場放射線治療の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外部放射線療法
• 定位放射線治療
• 世界の転移性尿路上皮がん市場膀胱内療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• カルメット・ゲラン菌療法
• 化学療法に基づく膀胱内療法

第7章 地域別・国別分析

• 世界の転移性尿路上皮がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の転移性尿路上皮がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 転移性尿路上皮がん市場：競合情勢
• 転移性尿路上皮がん市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co., Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Bayer Aktiengesellschaft
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Eli Lilly and Company
• Gilead Sciences Inc.
• Merck KGaA
• Astellas Pharma Inc.
• Genentech Inc.
• Genentech Inc.
• Exelixis Inc.
• EMD Serono
• Zymeworks Inc.
• Mirati Therapeutics Inc.
• UroGen Pharma Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 転移性尿路上皮がん市場2029：新たな機会を提供する国
• 転移性尿路上皮がん市場2029：新たな機会を提供するセグメント
• 転移性尿路上皮がん市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Metastatic urothelial carcinoma is an advanced form of bladder cancer where the cancer has spread beyond the urothelium to distant organs or lymph nodes. Treatment for metastatic urothelial carcinoma involves advanced diagnostic technologies, targeted therapies, and immunotherapies to manage and treat cancer that has spread beyond the bladder or urinary tract.

The primary treatment options for metastatic urothelial carcinoma include chemotherapy, targeted therapy, immunotherapy, radiation therapy, and intravesical therapy. Chemotherapy uses drugs to kill cancer cells or inhibit their growth. Diagnostic methods for detecting this cancer include urine lab tests, cystoscopy, intravenous pyelogram (IVP), and biopsy. Treatments can include medications, lifestyle changes, and other therapies, with administration routes such as oral, parenteral, and others. These treatments are utilized in various settings, including hospitals, oncology clinics, research institutes, and other healthcare facilities.

The metastatic urothelial carcinoma market research report is one of a series of new reports from The Business Research Company that provides metastatic urothelial carcinoma market statistics, including metastatic urothelial carcinoma industry global market size, regional shares, competitors with a metastatic urothelial carcinoma market share, detailed metastatic urothelial carcinoma market segments, market trends and opportunities, and any further data you may need to thrive in the metastatic urothelial carcinoma industry. This metastatic urothelial carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metastatic urothelial carcinoma market size has grown exponentially in recent years. It will grow from $1.18 billion in 2024 to $1.42 billion in 2025 at a compound annual growth rate (CAGR) of 20.2%. The growth during the historic period can be attributed to a favorable regulatory environment, the rising incidence of smoking-related cancers, the emergence of combination therapies, supportive government policies, and increased awareness and early diagnosis of metastatic urothelial carcinoma.

The metastatic urothelial carcinoma market size is expected to see rapid growth in the next few years. It will grow to $2.94 billion in 2029 at a compound annual growth rate (CAGR) of 19.9%. The growth in the forecast period can be attributed to increased patient advocacy, government programs supporting cancer care, the growth of the biopharmaceutical industry, the rising application of chemotherapy, and rapid urbanization and lifestyle changes. Major trends expected during this period include advancements in immunotherapy, the integration of artificial intelligence, collaborations between pharmaceutical and biotech companies, advancements in telemedicine, and the development of next-generation drugs.

The increasing incidence of bladder cancer is expected to drive the growth of the metastatic urothelial carcinoma market. Bladder cancer is a condition where malignant cells form in the bladder tissues, typically starting in the urothelial cells lining the bladder. The rise in bladder cancer cases is attributed to factors such as smoking, chemical exposure, chronic bladder inflammation, and improvements in detection methods. As metastatic urothelial carcinoma represents an advanced and aggressive stage of bladder cancer, it highlights the critical need for early detection, better treatment options, and increased research, ultimately fostering innovations in the management of bladder cancer and improving patient outcomes. For example, according to a February 2023 report from Cancer Research UK, the number of new bladder cancer cases in the UK is projected to rise from about 9,800 annually between 2023 and 2025 to around 10,700 cases per year by 2038-2040. This growing prevalence of bladder cancer is driving the expansion of the metastatic urothelial carcinoma market.

Regulatory approvals for new treatments are also contributing to the market's growth. Major companies in the metastatic urothelial carcinoma space are obtaining regulatory approvals for drugs, expanding their market reach and reinforcing their position in treating adult patients with locally advanced or metastatic urothelial carcinoma (la/mUC). Regulatory approvals involve the formal authorization granted by governmental bodies for drugs or treatments to be marketed to the public. For example, in April 2023, Merck & Co. Inc., a US-based pharmaceutical company, received FDA approval for KEYTRUDA (pembrolizumab) as a first-line treatment for certain patients with locally advanced or metastatic urothelial cancer. This approval marks a significant step in urothelial cancer treatment, as the combination of KEYTRUDA (pembrolizumab) and enfortumab vedotin became the first anti-PD-1 therapy approved in the U.S. in combination with an antibody-drug conjugate for patients with locally advanced or metastatic urothelial cancer. The combination therapy demonstrated a statistically significant improvement in overall survival (OS) and progression-free survival (PFS) when compared to traditional platinum-based chemotherapy, offering a new option for patients with limited treatment alternatives.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for an undisclosed amount. This acquisition enables Pfizer to enhance its oncology portfolio by integrating Seagen's innovative antibody-drug conjugate (ADC) technology and expanding its ability to develop targeted cancer therapies. This move strengthens Pfizer's leadership in cancer treatment and broadens its oncology product pipeline. Seagen, a US-based biotechnology company, specializes in therapies for metastatic urothelial carcinoma.

Major players in the metastatic urothelial carcinoma market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AbbVie Inc., Bayer AG, Bayer Aktiengesellschaft, Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Gilead Sciences Inc., Merck KGaA, Astellas Pharma Inc., Genentech Inc., Genentech Inc., Exelixis Inc., EMD Serono, Zymeworks Inc., Mirati Therapeutics Inc., UroGen Pharma Ltd.

North America was the largest region in the metastatic urothelial carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metastatic urothelial carcinoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metastatic urothelial carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metastatic urothelial carcinoma market consists of revenues earned by entities by providing services such as sales of surgical treatment, combination therapy and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic urothelial carcinoma market also includes sales of chemotherapy agents, immunotherapy drugs, tyrosine kinase inhibitors, adjuvant treatments, and targeted therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metastatic Urothelial Carcinoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metastatic urothelial carcinoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metastatic urothelial carcinoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metastatic urothelial carcinoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Chemotherapy; Targeted Therapy; Immunotherapy; Radiation Therapy; Intravesical Therapy
• 2) By Diagnosis: Urine Lab Tests; Cystoscopy; Intravenous Pyelogram (IVP); Biopsy
• 3) By End User: Hospital; Oncology Clinics; Research Institutes; Other End User
• Subsegments:
• 1) By Chemotherapy: Platinum-based Chemotherapy; Gemcitabine-based Chemotherapy; Other Chemotherapy Regimens
• 2) By Targeted Therapy: FGFR Inhibitors; Immune Checkpoint Inhibitors; Other Targeted Agents
• 3) By Immunotherapy: PD-1 Or PD-L1 Inhibitors; CTLA-4 Inhibitors; Combination Immunotherapies
• 4) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy
• 5) By Intravesical Therapy: Bacillus Calmette-Guerin Therapy; Chemotherapy-based Intravesical Therapy
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Metastatic Urothelial Carcinoma Market Characteristics

3. Metastatic Urothelial Carcinoma Market Trends And Strategies

4. Metastatic Urothelial Carcinoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Metastatic Urothelial Carcinoma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Metastatic Urothelial Carcinoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Metastatic Urothelial Carcinoma Market Growth Rate Analysis
• 5.4. Global Metastatic Urothelial Carcinoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Metastatic Urothelial Carcinoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Metastatic Urothelial Carcinoma Total Addressable Market (TAM)

6. Metastatic Urothelial Carcinoma Market Segmentation

• 6.1. Global Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Radiation Therapy
• Intravesical Therapy
• 6.2. Global Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urine Lab Tests
• Cystoscopy
• Intravenous Pyelogram (IVP)
• Biopsy
• 6.3. Global Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Oncology Clinics
• Research Institutes
• Other End Users
• 6.4. Global Metastatic Urothelial Carcinoma Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Platinum-based Chemotherapy
• Gemcitabine-based Chemotherapy
• Other Chemotherapy Regimens
• 6.5. Global Metastatic Urothelial Carcinoma Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• FGFR Inhibitors
• Immune Checkpoint Inhibitors
• Other Targeted Agents
• 6.6. Global Metastatic Urothelial Carcinoma Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PD-1 Or PD-L1 Inhibitors
• CTLA-4 Inhibitors
• Combination Immunotherapies
• 6.7. Global Metastatic Urothelial Carcinoma Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy
• Stereotactic Body Radiation Therapy
• 6.8. Global Metastatic Urothelial Carcinoma Market, Sub-Segmentation Of Intravesical Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bacillus Calmette-Guerin Therapy
• Chemotherapy-based Intravesical Therapy

7. Metastatic Urothelial Carcinoma Market Regional And Country Analysis

• 7.1. Global Metastatic Urothelial Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Metastatic Urothelial Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Metastatic Urothelial Carcinoma Market

• 8.1. Asia-Pacific Metastatic Urothelial Carcinoma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Metastatic Urothelial Carcinoma Market

• 9.1. China Metastatic Urothelial Carcinoma Market Overview
• 9.2. China Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Metastatic Urothelial Carcinoma Market

• 10.1. India Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Metastatic Urothelial Carcinoma Market

• 11.1. Japan Metastatic Urothelial Carcinoma Market Overview
• 11.2. Japan Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Metastatic Urothelial Carcinoma Market

• 12.1. Australia Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Metastatic Urothelial Carcinoma Market

• 13.1. Indonesia Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Metastatic Urothelial Carcinoma Market

• 14.1. South Korea Metastatic Urothelial Carcinoma Market Overview
• 14.2. South Korea Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Metastatic Urothelial Carcinoma Market

• 15.1. Western Europe Metastatic Urothelial Carcinoma Market Overview
• 15.2. Western Europe Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Metastatic Urothelial Carcinoma Market

• 16.1. UK Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Metastatic Urothelial Carcinoma Market

• 17.1. Germany Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Metastatic Urothelial Carcinoma Market

• 18.1. France Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Metastatic Urothelial Carcinoma Market

• 19.1. Italy Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Metastatic Urothelial Carcinoma Market

• 20.1. Spain Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Metastatic Urothelial Carcinoma Market

• 21.1. Eastern Europe Metastatic Urothelial Carcinoma Market Overview
• 21.2. Eastern Europe Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Metastatic Urothelial Carcinoma Market

• 22.1. Russia Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Metastatic Urothelial Carcinoma Market

• 23.1. North America Metastatic Urothelial Carcinoma Market Overview
• 23.2. North America Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Metastatic Urothelial Carcinoma Market

• 24.1. USA Metastatic Urothelial Carcinoma Market Overview
• 24.2. USA Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Metastatic Urothelial Carcinoma Market

• 25.1. Canada Metastatic Urothelial Carcinoma Market Overview
• 25.2. Canada Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Metastatic Urothelial Carcinoma Market

• 26.1. South America Metastatic Urothelial Carcinoma Market Overview
• 26.2. South America Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Metastatic Urothelial Carcinoma Market

• 27.1. Brazil Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Metastatic Urothelial Carcinoma Market

• 28.1. Middle East Metastatic Urothelial Carcinoma Market Overview
• 28.2. Middle East Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Metastatic Urothelial Carcinoma Market

• 29.1. Africa Metastatic Urothelial Carcinoma Market Overview
• 29.2. Africa Metastatic Urothelial Carcinoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Metastatic Urothelial Carcinoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Metastatic Urothelial Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Metastatic Urothelial Carcinoma Market Competitive Landscape And Company Profiles

• 30.1. Metastatic Urothelial Carcinoma Market Competitive Landscape
• 30.2. Metastatic Urothelial Carcinoma Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co., Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Metastatic Urothelial Carcinoma Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Bayer Aktiengesellschaft
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca PLC
• 31.5. Eli Lilly and Company
• 31.6. Gilead Sciences Inc.
• 31.7. Merck KGaA
• 31.8. Astellas Pharma Inc.
• 31.9. Genentech Inc.
• 31.10. Genentech Inc.
• 31.11. Exelixis Inc.
• 31.12. EMD Serono
• 31.13. Zymeworks Inc.
• 31.14. Mirati Therapeutics Inc.
• 31.15. UroGen Pharma Ltd.

32. Global Metastatic Urothelial Carcinoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metastatic Urothelial Carcinoma Market

34. Recent Developments In The Metastatic Urothelial Carcinoma Market

35. Metastatic Urothelial Carcinoma Market High Potential Countries, Segments and Strategies

• 35.1 Metastatic Urothelial Carcinoma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Metastatic Urothelial Carcinoma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Metastatic Urothelial Carcinoma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer